KEYMED BIO-B News

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTEXCLUSIVE LICENSE AGREEMENT FOR CM336

Nov 17 18:04

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024

Nov 1 16:36

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024

Oct 2 16:34

KEYMED BIO-B: INSIDE INFORMATION ANNOUNCEMENTSTAPOKIBART WAS GRANTED MARKETING APPROVAL FROMNATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR THETREATMENT OF MODERATE-TO-SEVEREATOPIC DERMATITIS IN ADULTS

Sep 12 18:15

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024

Sep 2 16:54

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024

Aug 2 16:35

KEYMED BIO-B: INSIDE INFORMATION -EXCLUSIVE LICENSE AGREEMENTFOR CM512 AND CM536

Jul 9 08:15

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024

Jul 4 17:01

KEYMED BIO-B: SIXTH AMENDED AND RESTATEDMEMORANDUM AND ARTICLES OF ASSOCIATION

Jun 25 20:14

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT RESULTS FROM AN EXPLORATORY CLINICAL STUDY OF CM313 IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA WERE RECENTLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

Jun 20 08:15

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTNEW DRUG APPLICATION OF STAPOKIBART INJECTION FORTHE TREATMENT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPSACCEPTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Jun 7 08:00

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024

Jun 5 16:43

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTLONG-TERM EFFICACY AND SAFETY DATA FROM A PHASE IIICLINICAL TRIAL OF STAPOKIBART INJECTION AT THEEUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY(EAACI) CONGRESS 2024

Jun 3 08:15

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTTHE LATEST RESULTS FROM A PHASE I CLINICAL STUDY OFCMG901 (AZD0901) AT THE ASCO ANNUAL MEETING 2024 BY WAY OFORAL PRESENTATION

Jun 2 18:06

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTSTAPOKIBART INJECTION INCLUDED IN THE PRIORITYREVIEW AND APPROVAL PROCEDURES FOR THE TREATMENTOF CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS

May 23 16:30

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024

May 6 16:34

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTNEW DRUG APPLICATION OF STAPOKIBART INJECTION FORTHE TREATMENT OF SEASONAL ALLERGIC RHINITIS ACCEPTEDBY NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Apr 30 08:15

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTPHASE III CLINICAL TRIAL OF STAPOKIBART INJECTIONFOR THE TREATMENT OF SEASONAL ALLERGICRHINITIS ACHIEVED PRIMARY ENDPOINTS

Apr 28 18:04

KEYMED BIO-B: Notification Letter to Non-registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications

Apr 24 16:37

KEYMED BIO-B: Notification Letter to Registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications

Apr 24 16:35